Text Size
Trial record 8 of 18 for:    "Gaucher disease type 1"
Previous Study | Return to List | Next Study

Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease

This treatment has been approved for sale to the public.
Sponsor:
Information provided by (Responsible Party):
Shire Human Genetic Therapies, Inc.
ClinicalTrials.gov Identifier:
NCT00954460
First received: August 5, 2009
Last updated: June 26, 2012
Last verified: June 2012
History of Changes
  Purpose

Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this treatment protocol is to observe the safety of velaglucerase alfa in patients with type 1 Gaucher disease who are either treatment naive (newly diagnosed) or who are currently being treated with the Enzyme Replacement Therapy (ERT) imiglucerase.


Condition Intervention
Gaucher Disease, Type 1
 Drug: velaglucerase alfa

Study Type: Expanded Access     What is Expanded Access?
Official Title: Multicenter Open-Label Treatment Protocol to Observe the Safety of Gene-Activated™ Human Glucocerebrosidase (GA-GCB, Velaglucerase Alfa) ERT in Newly Diagnosed or Previously Treated (With Imiglucerase) Patients With Type 1 Gaucher Disease

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Shire Human Genetic Therapies, Inc.:

Intervention Details:
    Drug: velaglucerase alfa
    up to 60 U/kg, every other week via intravenous infusion
    Other Names:
    • VPRIV
    • Gene activated human glucocerebrosidase
    • GA-GCB
Detailed Description:

Type 1 Gaucher disease, the most common form, accounts for more than 90% of all cases of Gaucher disease and does not involve the CNS. Typical manifestations of type 1 Gaucher disease include hepatomegaly, splenomegaly, thrombocytopenia, bleeding tendencies, anemia, hypermetabolism, skeletal pathology, growth retardation, pulmonary disease, and decreased quality of life. Velaglucerase alfa (Gene-Activated™ human glucocerebrosidase;GA-GCB) is produced in a continuous human cell line using proprietary gene-activation technology and has an identical amino acid sequence to the naturally occurring human enzyme. Velaglucerase alfa contains terminal mannose residues that target the enzyme to the macrophages-the primary target cells in Gaucher disease. This treatment protocol will observe the safety of velaglucerase alfa in patients with type 1 Gaucher disease who are either treatment naive (newly diagnosed) or who are currently being treated with the Enzyme Replacement Therapy (ERT) imiglucerase. Patients currently being treated with ERT for their Gaucher disease will receive the same number of units of velaglucerase alfa per month as their imiglucerase dose for doses between 30-120 U/kg/month. For patients who experienced dose reductions in their imiglucerase treatment due to supply constraints the pre-reduction monthly dose may be used to determine the monthly dose of velaglucerase alfa.

  Eligibility

Ages Eligible for Study:   3 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  1. The patient has a documented diagnosis of type 1 Gaucher disease
  2. The patient is > 2 years of age
  3. The patient has NOT previously experienced an anaphylactic or anaphylactoid reaction to another ERT including imiglucerase
  4. Women of child-bearing potential must agree to use a medically acceptable method of contraception at all times during the study; and must have a negative result to a pregnancy test as required throughout their participation in the study. Male patients must use a medically acceptable method of birth control throughout their participation in the study and must report their partner's pregnancy.
  5. The patient is sufficiently cooperative to participate in this treatment plan as judged by the Investigator

  6. If the patient is naïve or new to treatment, the patient has one or more of the following (in absence of the following criteria, please call the sponsor for treatment justification):

    • Gaucher disease-related anemia
    • Moderate splenomegaly (2 to 3 cm below the left costal margin), by palpation
    • Gaucher disease-related thrombocytopenia
    • Gaucher disease-related palpable enlarged liver

Exclusion Criteria: None

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00954460

  Show 32 Study Locations
Sponsors and Collaborators
Shire Human Genetic Therapies, Inc.
Investigators
Study Director: Gabriel M. Cohn, M.D. Shire Human Genetic Therapies, Inc.
  More Information

No publications provided

Responsible Party: Shire Human Genetic Therapies, Inc.
ClinicalTrials.gov Identifier: NCT00954460     History of Changes
Other Study ID Numbers: HGT-GCB-058
Study First Received: August 5, 2009
Last Updated: June 26, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Shire Human Genetic Therapies, Inc.:
VPRIV
Enzyme Replacement Therapy
Gaucher disease
glucocerebrosidase
beta-glucocerebrosidase
 Acid beta-glucocerebrosidase
glucosylceramidase
D-glucosyl-N-acylsphingosine glucohydrolase
gene activation
human

Additional relevant MeSH terms:
Gaucher Disease
Sphingolipidoses
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
 Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipidoses
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on June 17, 2013